Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer.

Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish MR, Warusavitarne J.

Histopathology. 2014 Aug;65(2):155-63. doi: 10.1111/his.12295. Epub 2014 May 12.

PMID:
24118100
2.

Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.

Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlén M, Jirström K, Eberhard J.

Diagn Pathol. 2012 Aug 30;7:115. doi: 10.1186/1746-1596-7-115.

3.

SATB1 is an independent prognostic marker for gastric cancer in a Chinese population.

Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q.

Oncol Rep. 2010 Oct;24(4):981-7.

PMID:
20811679
4.

SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma.

Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Kuteeva E, Johannesson H, Jirström K, Eberhard J.

Virchows Arch. 2014 Dec;465(6):649-59. doi: 10.1007/s00428-014-1667-6. Epub 2014 Oct 19.

5.

Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.

Elebro J, Heby M, Gaber A, Nodin B, Jonsson L, Fristedt R, Uhlén M, Jirström K, Eberhard J.

J Transl Med. 2014 Oct 17;12:289. doi: 10.1186/s12967-014-0289-8.

6.

Expression of SATB1 promotes the growth and metastasis of colorectal cancer.

Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B, Zhao M, Wei M, Ye C, Sun Y, Yuan X, Yang C, Hao C.

PLoS One. 2014 Jun 27;9(6):e100413. doi: 10.1371/journal.pone.0100413. eCollection 2014.

7.

Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues.

Kowalczyk AE, Godlewski J, Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, Kwiatkowski P, Pula B, Dziegiel P, Janiszewski J, Wierzbicki PM, Kmiec Z.

Tumour Biol. 2015 Jun;36(6):4441-52. doi: 10.1007/s13277-015-3084-0. Epub 2015 Jan 21.

8.

Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma.

Niu Y, Wang L, Cheng C, Du C, Lu X, Wang G, Liu J.

APMIS. 2015 Feb;123(2):93-101. doi: 10.1111/apm.12310. Epub 2014 Sep 25.

PMID:
25257341
9.

Overexpression of special AT-rich sequence-binding protein 1 in endometrial cancer: a clinicopathologic study.

Zhang Y, Wang L, Liu Y, Meng F, Wang S, Shang P, Gao Y, Chen X.

Int J Gynecol Cancer. 2015 Jan;25(1):4-11. doi: 10.1097/IGC.0000000000000314.

PMID:
25347096
10.

SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo.

Zhang J, Zhang B, Zhang X, Sun Y, Wei X, McNutt MA, Lu S, Liu Y, Zhang D, Wang M, Lin Z, Niu N.

PLoS One. 2013;8(1):e47902. doi: 10.1371/journal.pone.0047902. Epub 2013 Jan 11.

11.

Pilot study special AT-rich sequence-binding protein 1 investigating as a potential biomarker for esophageal squamous cell carcinoma.

Cong QX, Zhang H, Sun SX, Li HF, Wang Y, Jian S.

Dis Esophagus. 2016 Aug;29(6):621-6. doi: 10.1111/dote.12365. Epub 2015 May 8.

PMID:
25951709
12.

Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.

Liu X, Zheng Y, Qiao C, Qv F, Wang J, Ding B, Sun Y, Wang Y.

Diagn Pathol. 2015 May 9;10:50. doi: 10.1186/s13000-015-0282-4.

13.

Identification of SATB1 as a Specific Biomarker for Lymph Node Metastasis in Colorectal Cancer.

Baba H, Ishikawa T, Mogushi K, Ishiguro M, Uetake H, Tanaka H, Sugihara K.

Anticancer Res. 2016 Aug;36(8):4069-76.

PMID:
27466515
14.

SATB1 is Down-regulated in Clear Cell Renal Cell Carcinoma and Correlates with miR-21-5p Overexpression and Poor Prognosis.

Kowalczyk AE, Krazinski BE, Godlewski J, Grzegrzolka J, Kiewisz J, Kwiatkowski P, Sliwinska-Jewsiewicka A, Dziegiel P, Kmiec Z.

Cancer Genomics Proteomics. 2016 May-Jun;13(3):209-17.

PMID:
27107063
15.

Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer.

Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, Qiu MZ, Luo HY, Zhang DS, Xu RH.

World J Gastroenterol. 2014 Dec 28;20(48):18404-12. doi: 10.3748/wjg.v20.i48.18404.

16.

DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.

Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z.

BMC Cancer. 2013 Jul 31;13:366. doi: 10.1186/1471-2407-13-366.

17.

SATB1 expression is correlated with β-catenin associated epithelial-mesenchymal transition in colorectal cancer.

Lv JH, Wang F, Shen MH, Wang X, Zhou XJ.

Cancer Biol Ther. 2016;17(3):254-61. doi: 10.1080/15384047.2016.1139239. Epub 2016 Jan 25.

18.

Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features.

Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q.

APMIS. 2010 Nov;118(11):855-63. doi: 10.1111/j.1600-0463.2010.02673.x. Epub 2010 Sep 2.

PMID:
20955458
19.

SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer.

Mansour MA, Hyodo T, Akter KA, Kokuryo T, Uehara K, Nagino M, Senga T.

Oncotarget. 2016 Jan 26;7(4):4993-5006. doi: 10.18632/oncotarget.6651.

20.

p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer.

Yuan XS, Zhang Y, Guan XY, Dong B, Zhao M, Mao LL, Lu YY, Tian XY, Hao CY.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1211-20. doi: 10.1007/s00432-013-1434-0. Epub 2013 Apr 11.

PMID:
23576022

Supplemental Content

Support Center